Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration

摘要

The disclosure relates to the use R,R-formoterol for treating a patient having chronic obstructive pulmonary disease (COPD), comprising administering to the patient, with a high efficiency nebulizer, a dose of a R,R-formoterol (arformoterol) at a dose of 1 µg to about 15 µg. The treatment produces clinically meaningful bronchodilation for at least 24 hours.